实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (4): 360-366.doi: 10.11904/j.issn.1002-3070.2023.04.010

• 临床研究 • 上一篇    下一篇

B7-H4在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性分析

陈飞1, 王颖2, 曾传琴1   

  1. 1.四川大学华西广安医院病理科(广安 638000);
    2.四川大学华西广安医院肿瘤科
  • 收稿日期:2022-06-08 修回日期:2023-07-24 出版日期:2023-08-28 发布日期:2023-12-12
  • 通讯作者: 王颖,E-mail:wangying_lucky1979@163.com
  • 作者简介:陈飞,男,(1979-),本科,副主任医师,从事肿瘤诊断方向的研究。

Expression of B7-H4 in breast cancer tissues and its correlation with axillary lymph node metastasis in patients after neoadjuvant chemotherapy

CHEN Fei1, WANG Ying2, ZENG Chuanqin1   

  1. 1. Department of Pathology, West China Guang′an Hospital, Sichuan University, Guang′an 638000, China;
    2. Department of Oncology, West China Guang′an Hospital, Sichuan University
  • Received:2022-06-08 Revised:2023-07-24 Online:2023-08-28 Published:2023-12-12

摘要: 目的 探究B7同源体4(B7-H4)在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性。方法 选取2020年1月—2022年6月在我院接受新辅助化疗的82例乳腺癌患者为研究对象,采用活组织检查法评估肿瘤的病理类型,经新辅助化疗及乳腺癌改良根治术后获取乳腺癌组织和癌旁正常组织样本,采用免疫组化分析组织中B7-H4的表达。根据术后患者的病理确诊情况分为腋窝淋巴结转移组和腋窝淋巴结未转移组,采用单因素及多因素logistic回归分析影响新辅助化疗后淋巴结转移情况的因素。采用受试者工作特征(ROC)曲线分析B7-H4对乳腺癌患者新辅助化疗后腋窝淋巴结转移的诊断价值。构建列线图模型,采用ROC曲线和校准曲线对列线图模型的区分度和准确性进行验证。结果 B7-H4在乳腺癌组织中的阳性表达率高于癌旁组织(85.37% vs. 9.76%,P<0.05)。多因素logistic回归分析结果显示,B7-H4表达情况、术前腋窝淋巴结阳性数目、新辅助化疗疗效、新辅助化疗后肿瘤T分期、ER状态、HER2状态、Ki-67表达情况和化疗完成周期数均为乳腺癌患者新辅助化疗后腋窝淋巴结转移的危险因素(P<0.05);B7-H4诊断腋窝淋巴结转移的ROC曲线下面积为0.783(95% CI:0.738~0.836,P<0.001);C-index为0.819(95% CI:0.722~0.903,P<0.001),参考曲线和拟合曲线吻合度良好,列线图显示出良好的区分度和准确性。结论 B7-H4在乳腺癌组织中高表达,其高表达与患者新辅助化疗后腋窝淋巴结转移有关。

关键词: B7同源体4, 乳腺癌, 新辅助化疗, 腋窝淋巴结转移, 危险因素

Abstract: Objective The aim of this study was to explore the expression of B7 homologou 4(B7-H4)in breast cancer tissues, and its correlation with axillary lymph node metastasis in patients after neoadjuvant chemotherapy. Methods A total of 82 patients with breast cancer who received neoadjuvant chemotherapy in our hospital from January 2020 to June 2022 were selected as the subjects. Biopsies were used to evaluate the pathological types of tumors. After neoadjuvant chemotherapy and modified radical mastectomy for breast cancer, breast cancer tissue and adjacent normal tissue samples were obtained, and immunohistochemistry was used to analyze the expression of B7-H4 in tissues. According to the pathological diagnosis of postoperative patients, they were divided into the axillary lymph node metastasis group and the axillary lymph node non-metastasis group. Univariate and multivariate logistic regression were used to analyze the factors affecting lymph node metastasis after neoadjuvant chemotherapy. The receiver operating characteristic(ROC)curve was used to analyze the diagnostic value of B7-H4 for axillary lymph node metastasis in breast cancer patients after neoadjuvant chemotherapy. A nomogram model was constructed, and the ROC curve and calibration curve were used to verify the discrimination and accuracy of nomogram model. Results The positive rate of B7-H4 expression in breast cancer tissue was higher than that of adjacent tissue(85.37% vs. 9.76%, P<0.05). Multivariate logistic regression analyses showed that B7-H4 expression, the number of positive axillary lymph nodes before surgery, the efficacy of neoadjuvant chemotherapy, the tumor T stage after neoadjuvant chemotherapy, ER status, HER2 status, Ki-67 expression, and the number of cycles for chemotherapy completion were risk factors for axillary lymph node metastasis in breast cancer patients after neoadjuvant chemotherapy(P<0.05). The area under the ROC curve for B7-H4 in diagnosing axillary lymph node metastasis was 0.783(95% CI:0.738-0.836, P<0.001). C-index was 0.819(95% CI:0.722-0.903, P<0.001), the reference curve and the fitting curve had a good agreement, and the nomogram showed good discrimination and accuracy. Conclusion B7-H4 is highly expressed in breast cancer tissues, and its high expression is positively correlated with axillary lymph node metastasis in patients after neoadjuvant chemotherapy.

Key words: B7 homologue 4, Breast cancer, Neoadjuvant chemotherapy, Axillary lymph node metastasis, Risk factor

中图分类号: